Cerus (NASDAQ:CERS) Rating Lowered to Hold at Wall Street Zen

Cerus (NASDAQ:CERS) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

Separately, TD Cowen reiterated a “buy” rating on shares of Cerus in a research report on Monday, January 12th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Cerus presently has a consensus rating of “Hold”.

Cerus Stock Down 5.4%

NASDAQ CERS opened at $1.93 on Friday. The company has a current ratio of 1.73, a quick ratio of 1.17 and a debt-to-equity ratio of 0.62. The company has a market cap of $370.89 million, a price-to-earnings ratio of -24.13 and a beta of 1.51. The company has a 50 day moving average of $2.31 and a 200-day moving average of $1.85. Cerus has a 1-year low of $1.12 and a 1-year high of $2.95.

Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.01). Cerus had a negative return on equity of 26.09% and a negative net margin of 7.58%.The business had revenue of $64.58 million for the quarter, compared to the consensus estimate of $59.31 million. On average, equities research analysts expect that Cerus will post -0.08 earnings per share for the current fiscal year.

Institutional Trading of Cerus

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Cerus by 0.6% in the third quarter. Vanguard Group Inc. now owns 10,783,986 shares of the biotechnology company’s stock valued at $17,147,000 after acquiring an additional 62,663 shares during the last quarter. Wasatch Advisors LP lifted its stake in Cerus by 2.6% during the second quarter. Wasatch Advisors LP now owns 8,533,758 shares of the biotechnology company’s stock worth $12,033,000 after purchasing an additional 213,917 shares during the last quarter. Millennium Management LLC lifted its stake in Cerus by 17.6% during the third quarter. Millennium Management LLC now owns 3,470,062 shares of the biotechnology company’s stock worth $5,517,000 after purchasing an additional 519,301 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Cerus by 38.6% in the 2nd quarter. Acadian Asset Management LLC now owns 2,632,304 shares of the biotechnology company’s stock valued at $3,710,000 after purchasing an additional 733,683 shares in the last quarter. Finally, Ieq Capital LLC boosted its holdings in shares of Cerus by 1.1% in the 4th quarter. Ieq Capital LLC now owns 2,423,741 shares of the biotechnology company’s stock valued at $4,993,000 after purchasing an additional 25,771 shares in the last quarter. Institutional investors and hedge funds own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.